Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction

Abstract

Yair Humberto González-Tuyub,1 Karla Daniela González-Iñiguez,1 Paula Catalina Lizarazo-Guiza,2 Sergio Ricardo García-García3 1Clinical Immunology and Allergy Service, ISSSTE Hospital Regional General, Ignacio Zaragoza, Ciudad de México, México; 2Medical Scientific Liaison, AstraZeneca, Ciudad de México, México; 3Clinical Research, HS Estudios Farmacoeconómicos SA de CV, Ciudad de México, MéxicoCorrespondence: Yair Humberto González-Tuyub, Clinical Immunology and Allergy Service, ISSSTE Hospital Regional General, Calz, Ignacio Zaragoza, 1840, Juan Escutia, Iztapalapa, 09100 Iztapalapa, Ciudad de México, México, Email [email protected]: Asthma is a health condition with worldwide relevance, evaluated based on the necessary treatment to control symptoms and exacerbations. Severe asthma is uncontrolled despite high doses of ICS-LABA and treatment for triggering factors. Severe eosinophilic asthma is characterized by an increase in eosinophils in the peripheral circulation, walls, and passages of the respiratory tract. Biologic treatments such as benralizumab have demonstrated effectiveness as aids in decreasing respiratory tract inflammation and improving the management of symptoms in patients living with asthma.Objective: To assess the efficacy and safety of benralizumab as an add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.Methods: Observational, analytic and ambispective study in 21 patients diagnosed with severe eosinophilic asthma treated with benralizumab, to determine the treatment’s effectiveness through the change in estimated respiratory function by spirometry through the forced expiratory volume in one second (FEV1) value, reduction in second controlling treatment, serum eosinophil reduction, change in the Asthma Control Test score and the Asthma Control Questionnaire test at 6 and 16 months of treatment.Results: An average difference of 241.43 mL (± 461.43) in FEV1 at 6 months was found, as well as an average FeNO reduction of 49.8 ppm and eosinophil reduction of 612.78 cells at 12 months of treatment, additionally, CSI requirements were reduced in 95% of patients.Conclusion: Benralizumab improved respiratory function as well as key biomarkers such as eosinophil count, exhaled nitric oxide fraction (FeNO), which reflected in a decreased requirement of inhaled corticosteroids and improved symptom control.Keywords: asthma, eosinophils, benralizumab, biologics, CSI-LABA therapy

Keywords

• asthma
• eosinophils
• benralizumab
• biologics
• csi-laba therapy